Frank Stegmeier

Dr. Stegmeier is the Chief Scientific Officer at KSQ Therapeutics, a biotechnology company that has built an industry-leading CRISPRomics platform to discover and develop next-generation cancer medicines. Prior to joining KSQ Therapeutics, Frank served as Head of Global Oncology Target Discovery at the Novartis Institutes for Biomedical Research (NIBR), where he was responsible for developing the early oncology drug discovery portfolio. Frank earned his Ph.D. in biology from MIT and was a Helen Hay Whitney postdoctoral fellow at Harvard Medical School.